Clinical Trial Search

Primary: Number of Participants With Treatment Success/Failure at Visit 5/Week 14 — 42; 40; 6; 136 Participants

Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2) (Last Observation Carried Forward [LOCF]…

Primary: Percent Change in LDL-C From Baseline To Day 510 — -41.15; 8.37 percent change — p=<.0001

Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041

Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158

Primary: Ocular Itching — 0.43; 0.40; 1.60; 1.81 score on a scale

Primary: Ocular Itching — 0.50; 0.49; 1.87; 1.93 score on a scale

Primary: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population — 11.3; 6.8; 8.3; 6.8…

Primary: Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy — 31; 42; 45 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109 — 2; 9; 2; 6…

Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) — 289 Participants

Primary: Change From Baseline in Average Daily Pain Score (ADPS) at Each Week — -0.14; -0.20; -0.37; -0.50 units on a scale

Primary: Overall Survival (OS) — 30.7; 27.1 Weeks — p=0.858

Primary: Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs) — 34 Participants

Primary: Number of Participants With Adverse Events — 193; 208; 395; 175 Participants